Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on February 10, 2014. The filing reports the entry into a Material Definitive Agreement to acquire Pharmacy Creations, LLC, a compounding pharmacy located in Randolph, New Jersey. The acquisition is intended to enable the Company to manufacture and distribute its patent-pending proprietary drug formulations.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the acquisition rather than the Company's operational financial results for a specific period.
- Base Purchase Price: $600,000 in cash, subject to adjustment based on Pharmacy Creations' EBITDA for the fiscal year ended December 31, 2013.
- Contingent Cash Consideration: Up to $50,000 payable if Pharmacy Creations generates revenue over $3,500,000 for the 12-month period ending March 31, 2015.
- Contingent Stock Consideration: Up to 215,910 shares of common stock, issuable based on revenue milestones for the 12-month period ending March 31, 2016 (full amount if revenue exceeds $7,500,000; pro-rated if between $3,500,000 and $7,500,000).
- Required Investment: The Company is obligated to invest an aggregate of $1,000,000 by March 31, 2016, into Pharmacy Creations' facilities, personnel, equipment, and marketing.
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Closing Conditions
The transaction represents a material change in the Company's business operations through the acquisition of a manufacturing facility. The closing is expected to occur on or prior to March 31, 2014, subject to customary conditions, including the entry into employment agreements with the sellers. The agreement may be terminated if closing conditions are not satisfied by the deadline.
Outlook, Risks, and Contingencies
Management anticipates the acquisition will facilitate the distribution of novel pharmaceutical solutions. However, the filing includes a cautionary note regarding forward-looking statements, highlighting several risks:
- Delay or failure of the transaction to close.
- Difficulties in the integration process.
- Failure to realize expected benefits.
- Regulatory developments impacting compounding pharmacies and outsourcing facilities.
Key Facts for Investor Verification
- Verify the final EBITDA calculation for Pharmacy Creations for the fiscal year ended December 31, 2013, to determine the exact base purchase price.
- Monitor the closing date to ensure it occurs on or before March 31, 2014.
- Track Pharmacy Creations' revenue performance against the $3.5 million and $7.5 million milestones to assess potential contingent stock issuance.
- Review future filings for updates on the $1,000,000 capital investment commitment and regulatory compliance status of the acquired facility.